Analytical Data
-
Gene name
NF1
- Application
-
Alternative Names
NF1；Neurofibromin
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P21359
-
Expression Region
1566-1837aa
-
AA Sequence
SSKFEEFMTRHQVHEKEEFKALKTLSIFYQAGTSKAGNPIFYYVARRFKTGQINGDLLIYHVLLTLKPYYAKPYEIVVDLTHTGPSNRFKTDFLSKWFVVFPGFAYDNVSAVYIYNCNSWVREYTKYHERLLTGLKGSKRLVFIDCPGKLAEHIEHEQQKLPAATLALEEDLKVFHNALKLAHKDTKVSIKVGSTAVQVTSAERTKVLGQSVFLNDIYYASEIEEICLVDENQFTLTIANQGTPLTFMHQECEAIVQSIIHIRTRWELSQPD
-
Molecular Weight
38.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Neurofibromatosis type 1 (NF1) is a common genetic disorder caused by mutations in the NF1 gene, which encodes neurofibromin, a protein that functions as a negative regulator of the RAS signaling pathway. The dysfunction of neurofibromin leads to uncontrolled cell growth and division, resulting in the development of benign tumors, particularly neurofibromas, as well as a range of neurological and developmental issues. Research into NF1 has focused on understanding the molecular mechanisms involved in the disease, the role of neurofibromin in regulating cellular processes, and the development of targeted therapies. Recombinant NF1 protein studies are crucial for dissecting the intricate functions of neurofibromin, as these proteins can be used in both in vitro and in vivo models to investigate how mutations affect its biochemical properties and cellular interactions. Furthermore, characterizing the structure and function of NF1 and its domains aids in identifying potential pharmacological targets and therapeutic approaches, providing hope for better management strategies for individuals with NF1. The ongoing efforts in this area are aimed not only at advancing our knowledge of NF1 pathology but also at improving the quality of life for affected patients through innovative treatment options.
